Massachusetts Institute of Technology

Washington Research Foundation

Oculon Corporation

University of Washington

John I Clark

George B Benedek

Loretta S Mengel

Simon H Friedman

Roelant J Siezen

Andrew G Farr

John A Thomson

Stacia A Smith

Mark W Orme

Kerry W Fowler

Louis J Theodore

Shahram Vaezy

George M Thurston

Xiao-Yan Li

Geroge B Benedek

Order-based analyses of cell and tissue structure

The present invention relate to methods and pharmaceutical reagents for decreasing the phase separation temperature and inhibiting the formation of high molecular with aggregates in eye lenses, thereby inhibiting or reversing cataract formation.

Chemical prevention or reversal of cataract by phase separation

Specific aspects of the cellular and humoral immune systems of a mammalian host are regulated by administering to the host a compound having a reactive immunoregulatory conformation whose precise three-dimensional structure is defined herein. Sorbinil, tolrestat, W-3681, and the other immunoregulatory agents described herein possess this reactive conformation and so are therapeutically useful for inhibiting delayed-type hypersensitivity, T-cell proliferation, and B-cell antibody production, without altering the normal cellularity of the immune system or the normal metabolites of the arachidonic acid pathway.

Immunoregulatory agents

The present invention relates to methods and pharmaceutical reagents for decreasing the phase separation temperature and inhibiting the formation of high molecular weight aggregates in eye lenses, thereby inhibiting or reversing cataract formation.

Specific aspects of the cellular and humoral immune systems of a mammalian host are regulated by administering to the host a compound having a reactive immunoregulatory conformation whose precise three-dimensional structure is defined herein. Sorbinil, tolrestat, WF-3681, and the other immunoregulatory agents described herein process this reactive conformation and so are therapeutically useful for inhibiting delayed-type hypersensitivity, T-cell proliferation, and B-cell antibody production, without altering the normal cellularity of the immune system or the normal metabolites of the arachidonic acid pathway.

Cataract formation in mammalian lenses can be prevented or reversed by applying a solution of an aldehyde, an acrylamide or a glycol to the lens under conditions that permit the solution to interact with the lens constituents.

Process for preventing or reversing cataract formation

Process for preventing or reversing cataract formation using acrylamides

Growing community of inventors

Seattle, WA, United States of America

John I Clark